Professional Documents
Culture Documents
GI Effects of NSAIDs and COX-2 Specific Inhibitors - 2005-4090S1 - 02 - FDA - Cryer
GI Effects of NSAIDs and COX-2 Specific Inhibitors - 2005-4090S1 - 02 - FDA - Cryer
GI Effects of NSAIDs and COX-2 Specific Inhibitors - 2005-4090S1 - 02 - FDA - Cryer
Kidney
Sodium and fluid retention Hyperkalemia Acute renal failure Hypertension
Platelet
Inhibition of aggregation leading to increased potential for bleeding
Upper GI
GERD Subepithelial petechial hemorrhages Erosions Ulcers Stomach > duodenum Bleeding Stomach duodenum Perforations/obstruction
Colon
Colitis Ulcers Strictures Diverticular bleed or perforation Collagenous colitis Relapse of IBD
40 30 20
Hemorrhage
Uncomplicated
Hemorrhage
10
Perforation Perforation
75
80
85
0 90 70
75
80
85
90
Arthritis Patients
Long-Term Endoscopy studies:
Endoscopic ulcers, mostly asymptomatic
Clinical events:
Symptomatic ulcers GI Bleeding Perforation Obstruction
Range Range
> 90 % > 90 % 15 % 15 % 5% 5% 10 to 30% 10 to 30% 4 to 10 % 4 to 10 %
SALICYLATES
Aspirina (Zorprin, Easprin) Diflunisal (Dolobid) Salsalate (Disalcid, Salflex) Choline salicylate (Trilisate) Magnesium salicylate (Magan)
COX-2 INHIBITORS
Celecoxib (Celebrex) Valdecoxib (Bextra)
Tolmetin (Tolectin)
Also available as over-the-counter preparations in the U.S. b Combination tablet of NSAID/synthetic prostaglandin E1 c Parenterally administered
a
Age (>65 years) History of GI ulceration History of upper GI ulcer complication Concomitant drugs (e.g. corticosteroids,
coumadin) Prescribed + Low-Dose Aspirin Multiple NSAIDS Prescribed + OTC NSAIDs Cardiovascular disease
Wolfe MM et al. N Engl J Med 1999;340:1888-1899
Gastroprotection
Use lowest effective NSAID dose Misoprostol Proton pump inhibitors
15
10 4.4
SALICYLATES
Aspirina (Zorprin, Easprin) Diflunisal (Dolobid) Salsalate (Disalcid, Salflex) Choline salicylate (Trilisate) Magnesium salicylate (Magan)
COX-2 INHIBITORS
Celecoxib (Celebrex) Valdecoxib (Bextra)
Tolmetin (Tolectin)
Also available as over-the-counter preparations in the U.S. b Combination tablet of NSAID/synthetic prostaglandin E1 c Parenterally administered
a
COX-1 Constitutive
COX-2 Inducible
Thromboxane
Prostaglandins
Hemostasis
Bakhle et al. Med Inflamm. 1996;5:305-323. Vane et al. Inflamm Res. 1995;44:1-10.
p = 0.02
p = 0.09 11 / 1441 20 / 1384 49 / 1384 30 / 1441
Annualized Incidence %
All Patients
3 2 1 0
6 5 4 3 2 1 0
p = 0.02 p = 0.04
5 / 1143 14 / 1101 32 / 1101 16 / 1143
p = 0.49
6 5 4 3 2 1 0
17 / 283
p = 0.92
6 / 298 6 / 283
14/ 298
Ulcer Complications
(%) 1
0 0
FDA Presentation. 2/7/01.
80
160 180
240
320
Days
P<0.001
4 .5
P=0.005
fenoprofen < 5-fold COX-2 selective ibuprofen tolmetin naproxen aspirin indomethacin ketoprofen flurbiprofen ketorolac
p < 0.05
19/2526
16/1597
Etodolac Naproxen
B
Annualized incidence, %
All Patients
p = 0.68
6/329 5/367
Etodolac Naproxen
All Patients
SALICYLATES
Aspirina (Zorprin, Easprin) Diflunisal (Dolobid) Salsalate (Disalcid, Salflex) Choline salicylate (Trilisate) Magnesium salicylate (Magan)
COX-2 INHIBITORS
Celecoxib (Celebrex) Valdecoxib (Bextra) Not Widely Appreciated Etodolac (Lodine) Meloxicam (Mobic) In Development Etoricoxib Parecoxibc Lumiracoxib Previously Available Rofecoxib (Vioxx)
Tolmetin (Tolectin)
Also available as over-the-counter preparations in the U.S. b Combination tablet of NSAID/synthetic prostaglandin E1 c Parenterally administered
a
Baseline
Percent of Baseline
80 60 40 20 0
* * *
Stomach
* *
Duodenum
(
*
Rectum
Risk of UGI bleeding with Different Formulations of Low-Dose Aspirin (< 325mg)
Relative Risk
Plain ASA
Gastric bleeding
Duodenal bleeding
Kelley et al, Lancet 1996; 348; 1413
95% CI
2.2 - 2.9 4.4 - 7.0
p = 0.02
p = 0.09 11 / 1441 20 / 1384 49 / 1384 30 / 1441
Annualized Incidence %
All Patients
3 2 1 0
6 5 4 3 2 1 0
p = 0.02 p = 0.04
5 / 1143 14 / 1101 32 / 1101 16 / 1143
p = 0.49
6 5 4 3 2 1 0
17 / 283
p = 0.92
6 / 298 6 / 283
14/ 298
Ulcer Complications
p < 0.05
19/2526
16/1597
Etodolac Naproxen
B
Annualized incidence, %
All Patients
p = 0.68
6/329 5/367
Etodolac Naproxen
All Patients
20%
*
16.1%
*
17.1%
Ulcer Incidence
15% 10%
5.8%
7.3%
5% 0%
N=
381
387
377
374
12
6 months
6 months
GI Complications (%)
1
GI Complications (%)
p = NS
25 20 15 10 5 0
p = NS
n=
143
144
n=
1
116
106
Patients with prior ulcer bleed on NSAID; ulcer healed and H. pylori negative or eradicated prior to randomization
COX-2 inhibitors were develop to reduced However, COX-2 inhibitors have been widely used
by patients not at high risk of NSAIDS GI effects.
Limitations of COX-2 Inhibitors: No great need for COX-2s in patients at low GI risk
No GI benefit in patients concurrently taking aspirin CV concerns may exist for some patients
For such patients, COX-2 inhibitors are an However, for patients taking low-dose aspirin or
when CV concerns exist clinicians may consider other strategies to reduce NSAIDs GI effects.